Prognostic impact of serum 25-hydroxivitamin D [25(OH)D] concentrations in patients with lymphoid malignancies

Hematology

Volumn 18, Issue 1, 2013, Pages 20-25

  Aref, Salah ^a   Ibrahim, Lamiaa ^a   Azmy, Emaad ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

CLL; NHL; Prognosis; Vit D

Indexed keywords

25 HYDROXYVITAMIN D; CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VITAMIN BLOOD LEVEL;

25-HYDROXYVITAMIN D 2; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84873498041     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000025     Document Type: Article

References (35)

1. Stephens JM. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther. 2005;12:460-6.
2. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol. 2009;19:84-8.
3. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26-34.
4. Lim U, Freedman DM, Hollis BW. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer. 2009;124:979-86.
5. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-9.
6. Lappe JM. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586-91.
7. Arlet JB, Callens C, Hermine O, Darnige L, Macintyre E, Pouchot J, et al. Chronic lymphocytic leukaemia responsive to vitamin D administration. Br J Haematol. 2012;156:148-9.
8. Toner CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc. 2010;110:1492-500.
9. Egan KM, Sosman JA, Blot WJ. Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst. 2005; 97:161-3.
10. http://www.mayomedicallaboratories.com.
11. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1, 25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res. 2000;87:214-20.
12. Luong K, Nguyen LT. The beneficial role of vitamin D and its analogs in cancer treatment and prevention. Crit Rev Oncol Hematol. 2009;73:192-201.
13. Shanafelt TD, Drake MT, Maurer MJ. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011; 117:1492-8.
14. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28:4191-8.
15. Hickish T, Cunningham D, Colston K. The effect of 1, 25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer. 1993;68:668-72.
16. Ramagopalan SV, Heger A, Berlanga AJ. ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease. Genome Res. 2010;20:1352-60.
17. Pepper C, Thomas A, Hoy T, Milligan D, Bentley P, Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood. 2003;101:2454-60.
18. Bai M. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol. 2001;14:1105-13.
19. Erber E, Maskarinec G, Lim U, Kolonel LN., Dietary Vitamin D and Risk of Non-Hodgkin Lymphoma: The Multiethnic Cohort. Br J Nutr. 2010;103:581-4.
20. Kricker A, Armstrong BK, Hughes AM, Goumas C, Smedby KE, Zheng T, et al. Interlymph Consortium. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer. 2008;122:144-54.
21. Armstrong BK, Kricker A. Sun exposure and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16: 396-400.
22. Freedman DM, Kimlin MG, Hoffbeck RW, Alexander BH, Linet MS. Multiple indicators of ambient and personal ultraviolet radiation exposure and risk of non-Hodgkin lymphoma (United States). J Photochem Photobiol B. 2010;101:321-5.
23. Purdue MP, Hartge P, Davis S, Cerhan JR, Colt JS, Cozen W, et al. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2007;18:989-99.
24. Smedby KE, Hjalgrim H, Melbye M, Torrång A, Rostgaard K, Munksgaard L, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97:199-209.
25. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, et al. Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control. 2006;17:1045-52.
26. Soni LK, Hou L, Gapstur SM, Weisenburger DD, Chiu BC. Sun exposure and non-Hodgkin lymphoma: A population-based, case-control study. Eur J Cancer. 2007;43:2388-95.
27. Bertrand KA, Chang ET, Abel GA, Zhang SM, Spiegelman D, Qureshi AA, et al. Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control. 2011;22:1731-41.
28. Chang ET, Canchola AJ, Cockburn M, Lu Y, Wang SS, Bernstein L, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood. 2011;118:1591-9.
29. Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG. A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults. Cancer Causes Control. 2010;21:1265-75.
30. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-6.
31. Polesel J, Talamini R, Montella M, Parpinel M, Dal Maso L, Crispo A, et al. Linoleic acid,vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian casecontrol study. Ann Oncol. 2006;17:713-8.
32. Chang ET, Balter KM, Torrang A, Smedby KE, Melbye M, Sundstrom C, et al. Nutrient intake and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2006;164:1222-32.
33. Raina V, Cunningham D, Gilchrist N, Soukop M. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer. 1991;63:463-5.
34. Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukemia. Br J Haematol. 2001;115:854-61.
35. Shanafelt TD, Witzig TE, Fink SR. Prospective evaluation of clonal evolution during long term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634-41.